Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TWST vs RAPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RAPT Captures Overall Composite Edge (52.4 HOLD vs 51.7 HOLD), While TWST Leads 5–1 on Growth & Valuation Pillars

RAPT Overall Winner 6-Pillar Tally: TWST 5 – 1 RAPT Matrix Metrics: TWST 3 – 5 RAPT

As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Twist Bioscience Corporation (TWST) on higher Unified Composite conviction (52.4/100 HOLD vs. 51.7/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality), while TWST wins 5–1 across the 6-pillar growth and valuation breakdown. TWST trades at $105.61 (N/M Forward P/E, -31.9% operating margin) versus RAPT at $58.02 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. TWST 51.7/100 HOLD) and -0.02β · 2% Vol risk profile, whereas TWST leads top-line expansion (+23.2% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TWST vs RAPT
TWST NASDAQ
Twist Bioscience Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$105.61
-5.37% 1D
Market Cap $7.6B
TTM Revenue $432M
Forward P/E N/M
Beta / 30D Vol 3.13β · 126% Vol
Unified Composite Score
51.7 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 36.1 · SMA20: $137.35 · SMA50: $149.85
RAPT NASDAQ Head-to-Head Winner
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap $1.7B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.02β · 2% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 61.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (27.1% over 20 days), RSI 80
RSI-14: 79.7 · SMA20: $57.82 · SMA50: $47.67

6-Pillar Scorecard Institutional Category Breakdown (TWST 5 – 1 RAPT)

Columns: Metric · TWST · RAPT
1. Valuation Multiples TWST
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 17.5x N/M
2. Growth & Scale TWST
Revenue Growth (YoY) +23.2% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $432M N/A
Market Cap $7.6B $1.7B
3. Profitability & Quality RAPT
Gross Margin 52.0% N/A
Operating Margin -31.9% 0.0%
Net Profit Margin -31.7% 0.0%
Return on Equity (ROE) -29.6% -85.4%
4. Balance Sheet & Cash Flow TWST
Cash Generation (TTM) -$115M EBITDA N/A
Cash Flow Margin -26.7% EBITDA Mgn N/A
Net Cash / Leverage $7.11 Book/Sh · -29.6% ROE $9.02 Book/Sh · -85.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TWST
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 93.2% (18th %ile) 0.8% (<1st %ile)
Put/Call OI Skew 1.04x (Balanced) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat TWST
OpEx & R&D Intensity 83.9% of Rev ($362M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TWST (3) vs RAPT (5)
Institutional Metric TWST RAPT Criterion Row Edge
Market Capitalization
Scale
$7.6B $1.7B Larger Scale TWST
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+23.2% -100.0% Higher Growth TWST
Operating Margin (TTM)
Profitability
-31.9% 0.0% Higher Margin RAPT
Net Profit Margin
Profitability
-31.7% 0.0% Higher Margin RAPT
Return on Equity (ROE)
Capital Efficiency
-29.6% -85.4% Higher ROE TWST
52-Week Range Position
Momentum
42% ($23–$220) 100% ($1–$58) Stronger Trend RAPT
Beta / 30D Volatility
Risk Regime
3.13β · 126% Vol -0.02β · 2% Vol Lower Realized Risk RAPT
Unified Institutional Score
Composite Signal
51.7 / 100 (HOLD) 52.4 / 100 (HOLD) Higher Composite RAPT
Trailing 12M Revenue (USD)
Operating Scale
$432M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
52.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 17.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$115M EBITDA ($7.11 Book/Sh · -29.6% ROE) N/A ($9.02 Book/Sh · -85.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TWST +9.69 pp
TWST: +10.37% · RAPT: +0.68%
3M Horizon RAPT +29.68 pp
TWST: +44.76% · RAPT: +74.44%
6M Horizon RAPT +31.16 pp
TWST: +70.79% · RAPT: +101.95%
1Y Horizon RAPT +31.16 pp
TWST: +70.79% · RAPT: +101.95%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TWST vs RAPT. Trailing 12-month operating profitability (TWST -31.9% vs RAPT 0.0%) and valuation multiples (TWST N/M vs RAPT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TWST ADR TTM Benchmark FX-Normalized USD
TTM Revenue$432M
Gross Margin52.0%
Op. Margin-31.9%
ROE / Fwd P/E-29.6% · N/M
RAPT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TWST CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 93.2%
IV Percentile 18th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TWST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RAPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RAPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TWST Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.6B market capitalization and -31.9% operating margin.
OpEx & R&D Reinvestment 83.9% of Rev ($362M)
90D Engineering Disclosures 0 Published · Spatial Genomics
RAPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TWST vs RAPT Key Questions & Quantitative Answers

As of Nov 16, 2026, RAPT Therapeutics, Inc. (RAPT) captures the overall head-to-head institutional edge over Twist Bioscience Corporation (TWST) on higher Unified Composite conviction (52.4/100 HOLD vs. 51.7/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality), while TWST wins 5–1 across the 6-pillar growth and valuation breakdown. TWST trades at $105.61 (N/M Forward P/E, -31.9% operating margin) versus RAPT at $58.02 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: RAPT earns the overall head-to-head edge with a stronger Unified Composite Score (52.4/100 HOLD vs. TWST 51.7/100 HOLD) and -0.02β · 2% Vol risk profile, whereas TWST leads top-line expansion (+23.2% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.

TWST leads the Growth & Scale pillar: TWST posts +23.2% YoY revenue growth and +0.0% YoY earnings growth on $432M TTM revenue (52.0% gross margin, -31.9% operating margin), compared with RAPT at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, TWST generates $432M in USD-normalized revenue versus N/A for RAPT. In operating R&D and SG&A reinvestment, TWST deploys 83.9% of Rev ($362M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RAPT.

TWST screens cheaper on headline valuation multiples. TWST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.5x EV/Revenue (-26.7% EBITDA margin), whereas RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TWST (-29.6% ROE) versus RAPT (-85.4% ROE) capital efficiency.

In options market volatility and institutional positioning, TWST carries 93.2% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.13β · 126% Vol realized risk). By comparison, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.